Asthma Drug Montelukast May Boost Immunotherapy Against Aggressive Cancers
A Northwestern University study finds that montelukast, an FDA-approved asthma drug that blocks CysLTR1, can reprogram pro-tumor neutrophils and slow tumor growth in mice and human tumor samples, improving immunotherapy responses across several cancers, including triple-negative breast cancer—potentially fast-tracked to trials since the drug is already approved.